Current Treatment Strategies: Collagen Vascular Diseases in Children

Palit, Aparna; Inamadar, Arun C.
November 2012
Indian Journal of Dermatology;Nov/Dec2012, Vol. 57 Issue 6, p449
Academic Journal
Of the various collagen vascular diseases seen in pediatric age group, discoid lupus erythematosus, systemic lupus erythematosus, neonatal lupus erythematosus, juvenile dermatomyositis and childhood scleroderma are common and of practical importance to clinicians. Various treatment modalities of these conditions have been discussed at length. Of these, some are conventional and routine, while others are used in challenging situations of these diseases. Autologous stem cell transplant, biological therapies, intravenous immunoglobulin and narrow band ultraviolet B are among the latest therapeutic options for these difficult-to-treat conditions in children.


Related Articles

  • Apheresis for lupus erythematosus. WallaceM, D.J. // Lupus;1999, Vol. 8 Issue 3, p174 

    Indications for the use of apheresis technologies in managing lupus erythematosus have undergone numerous conceptual changes since the procedure was automated in the 1960s and first attempted for systemic lupus erythematosus (SLE) in 1974. Once thought to be a promising treatment for a variety...

  • Diffuse alveolar hemorrhage in systemic lupus erythematosus: a retrospective study in China. Shen, M.; Zeng, X.; Tian, X.; Zhang, F.; Zhang, X.; Xu, W. // Lupus;Oct2010, Vol. 19 Issue 11, p1326 

    The objective of this study was to determine the clinical features of systemic lupus erythematosus (SLE) patients with diffuse alveolar hemorrhage (DAH). The medical records of 29 patients with DAH among 2133 SLE patients admitted to Peking Union Medical College Hospital from January 2004 to...

  • Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus. Kansal, Amit; Tripathi, Deepak; Rai, Mohit; Agarwal, Vikas // Clinical Rheumatology;Feb2016, Vol. 35 Issue 2, p341 

    Corticosteroids (CS) are the mainstay of treatment in systemic lupus erythematosus (SLE) patients. However, some patients have poor response to CS treatment. Among the multiple mechanisms of CS resistance, overexpression of P-glycoprotein (P-gp) on peripheral blood lymphocytes (PBL) may be one...

  • A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus. Tsakonas, E.; Joseph, L.; Esdaile, J.M.; Choquette, D.; Senecal, J.L.; Danoff, D.; Osterland, C.K.; Yeadon, C.; Smith, C.D. // Lupus;1998, Vol. 7 Issue 1, p80 

    The ability of antimalarials to moderate severe disease activity in systemic lupus erythematosus (SLE) is plausible but undemonstrated. We evaluated the long-term effectiveness of maintaining treatment with hydroxychloroquine sulphate (HCQ) to prevent major flares in quiescent SLE. Forty-seven...

  • High-dose cyclophosphamide for severe systemic lupus erythematosus. Gladstone, DE; Prestrud, AA; Styler, MJ; Topolsky, DL; Crilley, PA; Hoch, S; Huppert, A; Brodsky, I // Lupus;2002, Vol. 11 Issue 7, p405 

    Cytotoxic therapy is a cornerstone for patients with severe systemic lupus erythematosus (SLE). High-dose cyclophosphamide, 200mg/kg, can induce a complete remission without the need for stem cell rescue in patients with autoimmune illnesses. Here we report on our first four patients treated for...

  • High-dose intravenous cyclophosphamide therapy in severe SLE. D'Cruz, D // Lupus;2002, Vol. 11 Issue 7, p403 

    Reviews several studies on the application of high-dose intravenous cyclophosphamide therapy in severe systemic lupus erythematosus (SLE). Discussion on the effectiveness of the therapy; Prospect of the therapy.

  • Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus. Liang, Matthew H.; Simard, Julia F.; Costenbader, Karen; Dore, Benjamin T.; Ward, Michael; Fortin, Paul R.; Illei, Gabor G.; Manzi, Susan; Mittleman, Barbara; Buyon, Jill; Gupta, Samardeep; Abrahamowicz, Michal // Endocrine, Metabolic & Immune Disorders - Drug Targets;Mar2009, Vol. 9 Issue 1, p108 

    No new drugs have been approved for the treatment of systemic lupus erythematosus (SLE) by the Food and Drug Administration for the last 30 years. One barrier has been the lack of validated biomarkers and surrogate endpoints. Validation of SLE biomarkers in the past have been methodologically...

  • Q/What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus? Jones, Daniel W.; Wright, Derek; Jankowski, Terry Ann; Vincent, E. Chris // Journal of Family Practice;Oct2014, Vol. 63 Issue 10, p607 

    The article presents a medical research results to a clinical inquiry on the treatments to relieve arthritis and fatigue associated with systemic lupus erythematosus (SLE) in patients. It suggests the use for hydroxychloroquine and chloroquine to improve arthritis associated with mild SLE. It...

  • Biological Therapy in Systemic Lupus Erythematosus. Postal, Mariana; Costallat, Lilian T. L.; Appenzeller, Simone // International Journal of Rheumatology;2012, p1 

    Systemic lupus erythematosus (SLE) is a prototypic inflammatory autoimmune disorder characterized bymultisysteminvolvement and fluctuating disease activity. Symptoms range from rather mild manifestations such as rash or arthritis to life-threatening endorgan manifestations. Despite new and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics